Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

NCT02759614 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

311

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

Guangdong Association of Clinical Trials